全球慢性肾臟病药物市场：依药物类别、给药途径、适应症、通路及地区划分

预计2024年全球慢性肾臟病治疗市场规模将达151亿美元，2024年至2031年复合年增长率为5.2%，2031年将达215.5亿美元。

图：2024 年按地区分類的慢性肾臟病治疗药物市场占有率（%）

全球慢性肾臟病药物市场的成长是由全球肾臟病盛行率上升所推动的。慢性肾臟病（CKD）是指肾功能随着时间的推移逐渐衰退。如果不及时治疗，CKD 最终会导致肾衰竭和末期肾病变。 CKD 的常见原因包括糖尿病、高血压、肾丝球肾炎和多囊性肾病变。人口老化的增加和文明病的增加可能导致 CKD 盛行率的增加。慢性肾臟病药物旨在减缓疾病的进展、治疗併发症并维持整体肾臟健康。肾素-血管收缩素系统抑制剂、钙通道阻断剂、红血球生成刺激因子和利尿剂是用于治疗慢性肾臟病的主要药物类别。

市场动态：

全球慢性肾臟病药物市场的成长是由糖尿病和高血压盛行率上升所推动的。根据国际糖尿病联盟发布的资料，2021年全球约有5.37亿成年人将罹患糖尿病。预计到 2030 年，这一数字将增至 6.43 亿，到 2045 年将增至 7.83 亿。高血压也是 CKD 的一个主要原因。政府积极努力提高人们对肾臟疾病早期诊断和治疗的认识，这可能会推动市场成长。然而，新药认证的严格规定以及与长期治疗相关的严重副作用的风险可能会阻碍市场成长。联合治疗和标靶治疗的开发为慢性肾臟病药物行业的製造商提供了利润丰厚的机会。

本研究的主要特点

该报告对全球慢性肾臟病治疗市场进行了详细分析，包括以2023年为基准年的预测期（2024-2031年）的市场规模（十亿美元）和年复合成长率（CAGR%）。

它还揭示了各个细分市场的潜在商机，并说明了该市场有吸引力的投资提案矩阵。

它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要见解。

根据公司亮点、产品系列、主要亮点、绩效和策略等参数对全球慢性肾臟病药物市场的主要企业进行了分析。

本报告中的主要企业包括辉瑞公司、葛兰素史克公司、罗氏公司、赛诺菲公司、Keryx Biopharmaceuticals、Kissei Pharmaceutical Co. Ltd.、阿斯特捷利康公司和梯瓦製药工业有限公司。

该报告的见解使负责人和公司经营团队能够就未来的产品发布、升级、市场扩张和行销策略做出明智的决策。

全球慢性肾臟病药物市场报告迎合了该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。

透过用于分析全球慢性肾臟病治疗药物市场的各种策略矩阵，将有助于相关人员做出决策。

目录

第一章 研究目的与前提

• 研究目的
• 先决条件
• 简称

第二章 市场展望

• 报告说明
  • 市场定义和范围
• 执行摘要

第三章 市场动态、法规与趋势分析

• 市场动态
• 影响分析
• 主要亮点
• 监管场景
• 产品发布/核准
• PEST分析
• 波特的分析
• 併购场景

第四章全球慢性肾臟病药物市场，依药物类别，2019-2031（十亿美元）

• ACE抑制剂
• 血管收缩素受体阻断剂 (ARB)
• B阻断剂
• 钙离子通道阻断剂
• 袢利尿剂
• 红血球生成刺激因子（ESA）
• 磷酸盐粘合剂
• 其他的

第五章 全球慢性肾臟病治疗市场，依途径，2019-2031 年（十亿美元）

• 口服
• 胃肠外的

第六章 2019-2031 年全球慢性肾臟病药物市场（按适应症）（十亿美元）

• 糖尿病肾臟病
• 肾丝球肾炎
• 高血压肾臟病
• 多囊肾
• 其他适应症

第七章2019-2031年全球慢性肾臟病药物市场（按分销管道）（十亿美元）

• 医院药房
• 零售药房
• 网路药房

第八章2019-2031年全球慢性肾臟病药物市场（按地区）（十亿美元）

• 拉丁美洲
• 欧洲
• 亚太地区
• 中东

第9章 竞争格局

• AstraZeneca
• Amgen Inc.
• F. Hoffmann-La Roche Ltd.
• Pfizer, Inc.
• Sanofi
• GlaxoSmithKline plc（GSK）
• AbbVie Inc.
• Keryx Biopharmaceuticals, Inc.
• Kissei Pharmaceutical Co., Ltd.
• Regeneron Pharmaceuticals, Inc.
• Bayer AG
• Reata Pharmaceuticals, Inc.
• Ardelyx, Inc.
• Boehringer Ingelheim International GmbH
• Novo Nordisk A/S
• Novartis AG
• Johnson & Johnson
• Astellas Pharma Inc.
• Takeda Pharmaceutical Company Limited
• Akebia Therapeutics, Inc.

第10章分析师建议

• 命运之轮
• 分析师观点
• 一致的机会图

第十一章 参考文献与调查方法

• 参考
• 调查方法
• 关于出版商

Global chronic kidney disease drugs market is estimated to be valued at USD 15.10 Billion in 2024 and is expected to reach USD 21.55 Billion by 2031, exhibiting a compound annual growth rate (CAGR) of 5.2% from 2024 to 2031.

Figure. Chronic Kidney Disease Drugs Market Share (%), By Region 2024

Global chronic kidney disease drugs market h growth is driven by rising prevalence of kidney disorders worldwide. Chronic kidney disease (CKD) refers to the gradual loss of kidney function over time. If left untreated, CKD can eventually lead to kidney failure or end-stage renal disease. Some of the common causes of CKD include diabetes, high blood pressure, glomerulonephritis, and polycystic kidney disease. Growing geriatric populations and increasing lifestyle diseases can lead to increased prevalence of CKD. The chronic kidney disease drugs aim to slow down the progression of the disease, treat complications, and help maintain overall kidney health. Renin-angiotensin system inhibitors, calcium channel blockers, erythropoiesis-stimulating agents, and diuretics are some of the major drug classes used for managing chronic kidney diseases.

Market Dynamics:

Global chronic kidney disease drugs market growth is driven by rising prevalence of diabetes and hypertension as both are significant risk factors for CKD. According to the data published by the International Diabetes Federation, nearly 537 million adults lived with diabetes in 2021 across the globe. This number is anticipated to rise to 643 million by 2030 and 783 million by 2045. High blood pressure, or hypertension, is also a major culprit for CKD cases. Favorable government initiatives to spread awareness about early diagnosis and treatment of kidney diseases can drive the market growth. However, stringent regulations for new drug approval and the risk of severe side effects associated with long-term therapy can hamper the market growth. The development of combinational and targeted therapies presents lucrative opportunities for manufacturers in the chronic kidney disease drugs industry.

Key features of the study:

This report provides in-depth analysis of the global chronic kidney disease drugs market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global chronic kidney disease drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Pfizer Inc., GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd., Sanofi, Keryx Biopharmaceuticals, Kissei Pharmaceutical Co. Ltd., AstraZeneca plc, Teva Pharmaceutical Industries Ltd.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global chronic kidney disease drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic kidney disease drugs market

Detailed Segmentation-

• By Drug Class
  • ACE Inhibitors
  • Angiotensin Receptor Blockers (ARBs)
  • B-Blockers
  • Calcium Channel Blockers
  • Loop Diuretics
  • Erythropoiesis-Stimulating Agents (ESAs)
  • Phosphate Binders
  • Others
• By Route of Administration:
  • Oral
  • Parenteral
• By Indication
  • Diabetic Nephropathy
  • Glomerulonephritis
  • Hypertensive Nephropathy
  • Polycystic Kidney Disease
  • Other Indications
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
• Key Players Insights
  • AstraZeneca
  • Amgen Inc.
  • Hoffmann-La Roche Ltd.
  • Pfizer, Inc.
  • Sanofi
  • GlaxoSmithKline plc (GSK)
  • AbbVie Inc.
  • Keryx Biopharmaceuticals, Inc.
  • Kissei Pharmaceutical Co., Ltd.
  • Regeneron Pharmaceuticals, Inc.
  • Bayer AG
  • Reata Pharmaceuticals, Inc.
  • Ardelyx, Inc.
  • Boehringer Ingelheim International GmbH
  • Novo Nordisk A/S
  • Novartis AG
  • Johnson & Johnson
  • Astellas Pharma Inc.
  • Takeda Pharmaceutical Company Limited
  • Akebia Therapeutics, Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Chronic Kidney Disease Drugs Market, By Drug Class
  • Global Chronic Kidney Disease Drugs Market, By Route of Administration
  • Global Chronic Kidney Disease Drugs Market, By Indication
  • Global Chronic Kidney Disease Drugs Market, By Distribution Channel
  • Global Chronic Kidney Disease Drugs Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Chronic Kidney Disease Drugs Market, By Drug Class, 2019-2031, (USD Bn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• ACE Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Angiotensin Receptor Blockers (ARBs)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• B-Blockers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Calcium Channel Blockers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Loop Diuretics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Erythropoiesis-Stimulating Agents (ESAs)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Phosphate Binders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

5. Global Chronic Kidney Disease Drugs Market, By Route of Administration, 2019-2031, (USD Bn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Parentral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Chronic Kidney Disease Drugs Market, By Indication, 2019-2031, (USD Bn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Diabetic Nephropathy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Glomerulonephritis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Hypertensive Nephropathy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Polycystic Kidney Disease
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Other Indications
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Chronic Kidney Disease Drugs Market, By Distribution Channel, 2019-2031, (USD Bn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Chronic Kidney Disease Drugs Market, By Region, 2019 - 2031, (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2024,2027 & 2031, (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2019 - 2031, (USD Bn)
  • Regional Trends
    • North America
  • Introduction
  • Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, V (USD Bn)
  • Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, V (USD Bn)
  • Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, V (USD Bn)
  • Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, V (USD Bn)
  • Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, V (USD Bn)
  • Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
  • Introduction
  • Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, V (USD Bn)
  • Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Country/Region, 2019 - 2031, (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

9. Competitive Landscape

• AstraZeneca
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Amgen Inc.
• F. Hoffmann-La Roche Ltd.
• Pfizer, Inc.
• Sanofi
• GlaxoSmithKline plc (GSK)
• AbbVie Inc.
• Keryx Biopharmaceuticals, Inc.
• Kissei Pharmaceutical Co., Ltd.
• Regeneron Pharmaceuticals, Inc.
• Bayer AG
• Reata Pharmaceuticals, Inc.
• Ardelyx, Inc.
• Boehringer Ingelheim International GmbH
• Novo Nordisk A/S
• Novartis AG
• Johnson & Johnson
• Astellas Pharma Inc.
• Takeda Pharmaceutical Company Limited
• Akebia Therapeutics, Inc.

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us